Inhalable Living Biotherapeutics and Bio-Derived Organisms for Precision Theranostics of Lung Diseases
Advanced Clinical Engineering · 2026
DOI: 10.2738/ace.2026.0012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Clinical Engineering, 2026. Verfasst von Tong Li und 4 weiteren Autor:innen. Die Arbeit nennt 200 Literaturangaben.
Abstract (Originalsprache)
Pulmonary delivery offers a noninvasive route for localized and systemic therapy while reducing gastrointestinal degradation and first-pass metabolism. However, its clinical efficacy is limited by heterogeneous pulmonary deposition, mucus and mucociliary clearance, macrophage-mediated elimination, disease-associated microenvironmental remodeling, and instability of biological cargoes during formulation and aerosolization. These challenges have driven growing interest in living biotherapeutics and bio-derived systems. These systems provide intrinsic capabilities for environmental sensing, tissue interaction, cellular targeting, cargo protection, and, in selected cases, active migration within diseased tissues. This narrative review presents an overview of inhaled living biotherapeutics and bio-derived carriers for precision theranostics of lung diseases, encompassing bacteria, bacteriophages, microalgae, mammalian cells, extracellular vesicles (EVs), outer membrane vesicles (OMVs), cell membrane-derived vesicles, and related biological systems. We classify these platforms by biological identity, mechanism of action, and product configuration, highlighting how intrinsic properties govern pulmonary distribution, target recognition, therapeutic activity, and safety. We further examine four engineering strategies: biological reprogramming, cargo loading and biointerface engineering, formulation and preservation, and aerosol delivery engineering. Finally, we discuss challenges in immunogenicity, phenotypic stability, dose consistency, scalability, aerosolization damage, and regulatory translation, outlining considerations for reproducible potency, safety, and quality. Collectively, these advances may transform passive pulmonary deposition into adaptive, mechanism-guided precision theranostics.
Zitieren
APA
Li, T., Pang, T. C., Guo, L., Dong, C., & Chang, Y. (2026). Inhalable Living Biotherapeutics and Bio-Derived Organisms for Precision Theranostics of Lung Diseases. Advanced Clinical Engineering. https://doi.org/10.2738/ace.2026.0012
Vancouver
Li T, Pang TC, Guo L, Dong C, Chang Y. Inhalable Living Biotherapeutics and Bio-Derived Organisms for Precision Theranostics of Lung Diseases. Advanced Clinical Engineering. 2026. doi:10.2738/ace.2026.0012
BibTeX
@article{Li2026,
author = {Li, Tong and Pang, Tsz Chun and Guo, Limei and Dong, Cheng and Chang, Yun},
title = {Inhalable Living Biotherapeutics and Bio-Derived Organisms for Precision Theranostics of Lung Diseases},
journal = {Advanced Clinical Engineering},
year = {2026},
doi = {10.2738/ace.2026.0012}
}
EUVIMED